This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

5 Blue-Chip Stocks to Buy: Navellier

The following commentary comes from an independent investor or market observer as part of TheStreet's guest contributor program, which is separate from the company's news coverage.

NEW YORK ( InvestorPlace) -- Even with the political strife erupting around the globe, stocks logged their third straight month of gains this February. I expect this strong performance to continue and for the top stock picks to do even better in March as a fresh wave of buying pressure enters the market.

Whether you're one of those investors who has been riding the bench or you've been in the game all along, you want to have quality blue-chips in your portfolio. So I have put together a list of the top blue-chip stocks to buy to take advantage of this coming strength.

AutoZone (AZO)

AutoZone Inc. (AZO) remains my favorite blue-chip. The company will release earnings for its fiscal second quarter today, and I think we'll really see the stock take off. Analysts are currently forecasting that the company will post earnings of $3.06 per share and sales totaling $1.6 billion. AutoZone has a history of beating analysts' estimates, and I'm confident that the company will pull out another good surprise this time around.

The company has a history of buying back stock, which helps increase earnings per share and, thus, drives the share price higher. I expect it to post strong quarterly earnings, and when that happens, much of the investor hesitation that has surrounded the stock of late will fall away. Buy AZO when it's trading for less than $274.

Novo Nordisk (NVO)

Novo Nordisk (NVO - Get Report) is up more than 9% in the past month. In the latest quarter, the company announced that sales increased 23% and profits surged 70% thanks to strong sales, reaching $724 million. In addition to a fantastic earnings report, the company announced that it would be implementing a share repurchase program, which began on Feb. 2, and will be in effect until April 26. Novo is a leader in diabetes management and recent regulatory failures of competitors have given it the green light to increase market share. The company just expanded its leading pharmaceutical services to include mobile technology. Novo Nordisk has developed the first mobile application to help doctors diagnose bleeding disorders. The application, Coags Uncomplicated, allows doctors to input test results and provides a list of possible diagnoses and descriptions that helps speed up the diagnosis process. Continue purchasing shares of NVO at less than $135.
  • Related Article: 5 Slumping Consumer Blue Chips to Sell Now
  • 1 of 2

    Check Out Our Best Services for Investors

    Action Alerts PLUS

    Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

    Product Features:
    • $2.5+ million portfolio
    • Large-cap and dividend focus
    • Intraday trade alerts from Cramer
    Quant Ratings

    Access the tool that DOMINATES the Russell 2000 and the S&P 500.

    Product Features:
    • Buy, hold, or sell recommendations for over 4,300 stocks
    • Unlimited research reports on your favorite stocks
    • A custom stock screener
    Stocks Under $10

    David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

    Product Features:
    • Model portfolio
    • Stocks trading below $10
    • Intraday trade alerts
    14-Days Free
    Only $9.95
    14-Days Free
    Dividend Stock Advisor

    David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

    Product Features:
    • Diversified model portfolio of dividend stocks
    • Updates with exact steps to take - BUY, HOLD, SELL
    Trifecta Stocks

    Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

    Product Features:
    • Model Portfolio
    • Intra Day Trade alerts
    • Access to Quant Ratings
    Real Money

    More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

    Product Features:
    • Access to Jim Cramer's daily blog
    • Intraday commentary and news
    • Real-time trading forums
    Only $49.95
    14-Days Free
    14-Days Free
    BIDU $151.37 7.20%
    AZO $728.54 2.20%
    CMG $479.15 3.80%
    ILMN $141.08 1.90%
    NVO $48.47 -0.31%


    Chart of I:DJI
    DOW 15,888.33 +228.15 1.46%
    S&P 500 1,853.17 +24.09 1.32%
    NASDAQ 4,307.7790 +40.9420 0.96%

    Free Reports

    Top Rated Stocks Top Rated Funds Top Rated ETFs